The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ ...

Vertex’s new drug Journavx (suzetrigine) has been hailed as a scientific breakthrough because it allays pain without entering the brain, minimizing the risk of addiction and dependence that can ...

Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...